Search / Trial NCT00001572

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 3, 1999

Apply for Trial

Trial Information

Current as of May 23, 2024

Completed

Keywords

B Cell Lymphoma Bcl 2 Positive Tumor Immunization Induction Chemotherapy Lymphoma Vaccine Follicular Lymphoma Tumor Derived Immunoglobulin Idiotype

Description

The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a carrier protein (KLH) and administration with an emulsion-based adjuvant. The objectives of this study are: 1) to evaluate feasibility and toxicity of new vaccine formulations, and 2) to evaluate cellular and humoral immune responses against the unique idiotype of the patient's lymphoma. The goal of this study is to trea...

Gender

All

Eligibility criteria

  • INCLUSION CRITERIA:
  • Sample size: up to 30 patients.
  • Sex distribution: Male and female.
  • Age: Patients must be greater than or equal to 18 years old.
  • Patients must meet all of the following eligibility criteria:
  • Tissue diagnosis of: follicular small cleaved cell or follicular mixed lymphoma with surface IgM, IgA, or IgG phenotype with a monoclonal heavy and light chain. Pathology slides must be submitted to the NIH Pathology Department for review.
  • Stage III or IV lymphoma.
  • A single peripheral lymph node of at least 2x2 to 3x3 cm size and accessible for biopsy/harvest.
  • Karnofsky status greater than or equal to 70%.
  • Life expectancy of greater than 1 year.
  • Serum creatinine less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma.
  • Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or Gilbert's disease. SGOT/SGPT less than or equal to 3.5 x upper limit of normal.
  • Ability to give informed consent. Ability to return to clinic for adequate follow-up for the period that the protocol requires.
  • There are no gender or racial / ethnic restrictions on patient selection. This protocol is open to all genders and racial / ethnic groups.
  • EXCLUSION CRITERIA:
  • The presence of any exclusion criteria (listed below) will prohibit entry onto study:
  • Prior total body irradiation.
  • Presence of antibodies to HIV or hepatitis B surface antigen or other active infectious process.
  • Pregnant or lactation. Fertile men and women must plan to use an effective contraception. A beta-HCG level will be obtained in women of child-bearing potential.
  • Patients with previous or concomitant malignancy, regardless of site, except curatively treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in situ of the cervix.
  • Patient unwilling to give informed consent.
  • Failure to meet any of the eligibility criteria in Section 3.2.
  • Any medical or psychiatric condition that in the opinion of the protocol chairman would compromise the patient's ability to tolerate this treatment.
  • Patients with CNS lymphoma (current or previously treated) will not be eligible.

Attachments

readout_NCT00001572_2024-05-23.pdf

4.5 MB

NCT00001572_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0